




Repeated intravenous indocyanine green application to prove uterine perfusion during uterus transposition

Christhardt Kohler,¹ Pirkko Kettner,¹ Dirk Arnold,² Gero Puhl,³ Simone Marnitz,⁴ Andrea Plaikner ¹

¹Department of Special Operative and Oncologic Gynecology, Asklepios Kliniken Hamburg GmbH - Asklepios Altona, Hamburg, Germany

²Department of Oncology, Asklepios Kliniken Hamburg GmbH - Asklepios Altona, Hamburg, Germany

³Department of Surgery, Asklepios Kliniken Hamburg GmbH - Asklepios Altona, Hamburg, Germany

⁴Department of Radio-oncology, Medical Faculty of the University of Cologne, Cologne, Nordrhein-Westfalen, Germany

Correspondence to

Dr Andrea Plaikner, Department of Special Operative and Oncologic Gynecology, Asklepios Klinik Altona, 22763 Hamburg, Germany; an.plaikner@gmail.com

Accepted 14 June 2022

Published Online First
28 June 2022

Deep rectal or anal cancer in women younger than 40 years is a rare event. Pelvic chemoradiation is the standard of care for these entities. However, due to the high radiosensitivity of ovaries and endometrium, pelvic radiation stands in contrast to fertility preservation and must be discussed with the patient.¹ We present the case of a young patient with deep rectal cancer in whom uterine transposition was performed. As first described by Ribeiro et al, 2017,^{2,3} the uterus can be released from vaginal and parametrial attachments (including transection of uterine arteries) if sufficient blood

supply to the uterus is provided by anastomosis between the uterine and ovarian arteries. Due to the preservation of infundibulopelvic ligaments, a mobile uterus together with both adnexae can be fixed onto the anterior abdominal wall, and finally, the cervix uteri will be sutured to an umbilical fascia window to ensure menstruation and cervical secretion. Uterine necrosis is a major concern during this procedure, although it seems to be a rare event.² With repeated intravenous indocyanine green injections it is possible to check in real time the uterine perfusion during the surgery before and after transection

INTERNATIONAL JOURNAL OF
GYNECOLOGICAL CANCER

Repeated intravenous ICG application to proof uterine perfusion during uterus transposition

C. Köhler¹ P. Kettner¹, D. Arnold², G. Puhl³, S. Marnitz⁴, A. Plaikner¹



¹ Asklepios clinic Altona, Hamburg, Germany, Dep. of surgical and oncologic gynecology

² Asklepios clinic Altona, Hamburg, Germany, Dep. of hematology and oncology

³ Asklepios clinic Altona, Hamburg, Germany, Dep. of surgery

⁴ University of Cologne, Department of Radiation Oncology, CyberKnife and Radiotherapy

 @IJGConline

Copyright © 2020 BMJ Publishing Group Ltd, International Gynecological Cancer Society, & European Society of Gynaecological Oncology. All rights reserved.

 Check for updates

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Kohler C, Kettner P, Arnold D, et al. *Int J Gynecol Cancer* 2022;**32**:1479–1480.

Video 1 The case of a young patient diagnosed with deep rectal cancer. Due to a strong desire to maintain fertility, the patient underwent uterine transposition prior to the radiation therapy. During the surgery, uterine perfusion was repeatedly checked by intravenous indocyanine green injection to lower the risk of post-operative uterine necrosis.

Video article

of the uterine vessels to minimize the risk of uterine necrosis post-operatively.

Contributors All authors have contributed to this submission. AP acts as the guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

ORCID iD

Andrea Plaikner <http://orcid.org/0000-0003-4563-3357>

REFERENCES

- 1 Köhler C, Marnitz S, Biel P, *et al.* Successful delivery in a 39-year-old patient with anal cancer after fertility-preserving surgery followed by primary chemoradiation and low anti-Mullerian hormone level. *Oncology* 2016;91:295–8.
- 2 Ribeiro R, Rebolho JC, Tsumanuma FK, *et al.* Uterine transposition: technique and a case report. *Fertil Steril* 2017;108:320–4.
- 3 Odetto D, Saadi JM, Chacon CB, *et al.* Uterine transposition after radical trachelectomy. *Int J Gynecol Cancer* 2021;31:1374–9.